# Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

> **NCT00961844** · PHASE1,PHASE2 · TERMINATED · sponsor: **Steinar Aamdal** · enrollment: 15 (actual)

## Conditions studied

- Metastatic Malignant Melanoma

## Interventions

- **BIOLOGICAL:** Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00961844
- **Lead sponsor:** Steinar Aamdal
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-08
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Logistical problems
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00961844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00961844, "Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00961844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*